Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for aggressive brain cancer? early trial tests tinostamustine

NCT ID NCT05432375

First seen Jan 03, 2026 · Last updated May 24, 2026 · Updated 25 times

Summary

This early-phase study tested a new drug called tinostamustine in 10 people with a fast-growing brain cancer (glioblastoma) that has a specific genetic marker (unmethylated MGMT). The goal was to find a safe dose and see how the drug works after standard treatment. Participants received the drug once every three weeks for up to 12 cycles, and researchers monitored side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hospital Universitario Ramón y Cajal, Madrid, Spain

    Madrid, Spain

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain

    Barcelona, Spain

  • Kantonsspital

    Sankt Gallen, Switzerland

  • South Texas Accelerated Research Therapeutics (START)

    Madrid, Spain

  • University Hospital

    Zurich, Switzerland

Conditions

Explore the condition pages connected to this study.